Hémangiomes infantiles et β-bloquants en ORL
Nicolas Leboulanger(Hôpital Necker-Enfants Malades), Françoise Denoyelle(Hôpital Necker-Enfants Malades), E.N. Garabédian(Sorbonne Université), Amanda Cox(Sorbonne Université)
Annales françaises d Oto-rhino-laryngologie et de Pathologie Cervico-faciale
November 1, 2011
Cited by 0
Related Papers
GJB2 Mutations and Degree of Hearing Loss: A Multicenter Study
|The American Journal of Human Genetics|2005|558
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
|Journal of Clinical Investigation|2009|299
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma
|International Journal of Pediatric Otorhinolaryngology|2009|235
Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30‐year nationwide cohort of 1478 patients under 18 years of age
|British Journal of Haematology|2016|130